Blood Reviews
Volume 22, Issue 5 , Pages 261-281, September 2008

Immunodeficiency-associated lymphomas

  • Huy Tran

      Affiliations

    • Department of Haematology, Princess Alexandra Hospital, Ipswich Road, Brisbane, Queensland, 4102, Australia
  • ,
  • Jamie Nourse

      Affiliations

    • Clinical Immunohaematology Lab, Queensland Institute of Medical Research, Floor I, CBCRC Building, 300 Herston Rd, Brisbane, 4006, Queensland, Australia
  • ,
  • Sara Hall

      Affiliations

    • Department of Haematology, Princess Alexandra Hospital, Ipswich Road, Brisbane, Queensland, 4102, Australia
  • ,
  • Michael Green

      Affiliations

    • Genomics Research Centre, Gold Coast Campus, Griffith University, PMB 50 Gold Coast Mail Centre, Queensland, 9726, Australia
  • ,
  • Lyn Griffiths

      Affiliations

    • Genomics Research Centre, Gold Coast Campus, Griffith University, PMB 50 Gold Coast Mail Centre, Queensland, 9726, Australia
  • ,
  • Maher K. Gandhi

      Affiliations

    • Department of Haematology, Princess Alexandra Hospital, Ipswich Road, Brisbane, Queensland, 4102, Australia
    • Clinical Immunohaematology Lab, Queensland Institute of Medical Research, Floor I, CBCRC Building, 300 Herston Rd, Brisbane, 4006, Queensland, Australia
    • Corresponding Author InformationCorresponding author. Address: Clinical Immunohaematology Lab, Queensland Institute of Medical Research, Floor I, CBCRC Building, 300 Herston Rd, Brisbane, 4006, Queensland, Australia. Tel.: +61 7 3845 3792; fax: +61 7 3845 3510.

published online 06 May 2008.

Summary 

This article covers lymphoproliferative disorders in patients with primary or acquired immunodeficiencies. Primary immunodeficiences include Ataxia Telangiectasia and X-linked disorders such as Wiskott-Aldrich syndrome. Acquired immunodeficiencies predominantly occur in the setting of infection with the Human Immunodeficiency Virus or arise following immunosuppressive therapy administered after organ transplantation. The rising incidence of HIV throughout the world and the dramatic increase in transplant surgery since the 1990’s suggest that these lymphomas will remain an important health problem. Evidence for lymphoma developing as a result of treatment with methotrexate or Tumour Necrosis Factor Antagonists for autoimmune entities will also be reviewed. The lymphoproliferations that occur with immunodeficiency are extremely heterogenous. In part this reflects the diversity of the causal immune defect. The most striking clinical characteristic is the high frequency of extranodal disease. Frequently, these lymphomas are driven by viruses such as Epstein-Barr virus (EBV), although the lack of EBV in a proportion indicates that alternate pathways must also be involved in the pathogenesis. Lastly, discussion will centre on mechanisms utilized by lymphomas in the immunodeficient as these may have applications to lymphomas in the “immunocompetent”, by serving as a paradigm for the altered immunoregulatory environment present in many lymphoma sub-types.

Keywords: Immunodeficiency, Lymphoma, Ataxia Telangiectasia, Combined variable immunodeficiency disorder, Post-transplantation lymphoproliferative disorder, Epstein-barr virus, Human herpes virus 8, Methotrexate, Infliximab, Human immunodeficiency virus, Primary central nervous system lymphoma, Primary effusion lymphoma, Hodgkin’s lymphoma, Diffuse large B cell lymphoma, Rituximab

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0268-960X(08)00034-9

doi:10.1016/j.blre.2008.03.009

Blood Reviews
Volume 22, Issue 5 , Pages 261-281, September 2008